Abstract
Overview
Introduction
The global antibacterial market, valued at $25.5 billion in 2005, is highly
mature. Modest growth (CAGR 2001-2005: 5.1%) is fuelled by ageing,
immunosuppression and emerging resistances, especially in the hospital and
former niche markets (e.g. MRSA). The community market, however, is facing a
value loss following the patent expiries of several blockbusters (e.g.
Pfizer' s Zithromax) in 2005.
Scope
- In-depth analysis of the current antibacterial market situation across the
major Western markets
- Thorough assessment of underlying commercial and clinical influencers
shaping the antibacterial market
- Detailed sales forecasts for key antibacterial classes, molecules and
brands in each of the seven major markets
- Case study analysis of life-cycle-management strategies for Zithromax
(Pfizer), Rocephin (Roche) and Biaxin (Abbott) and assessment of their success
Report Highlights
In 2005 the global antibacterial market was valued at approximately $25.5
billion with a modest CAGR of 5.1% since 2001. The fastest growing classes
were the carbapenems, glycopeptides and "others" (e.g. Pfizer' s Zyvox
(linezolid)). The best selling drug was J&J' s/Sanofi-Aventis' s Levaquin
(levofloxacin) with global sales of $2.4 billion.
Although gram-positive infections such as MRSA have been a key focus over
recent years, Datamonitor' s opinion leader research revealed new concerns
about gram-negative organisms such as acinetobacter, pseudomonas and ESBL
producing strains.
Ageing, immunosuppression and resistances contribute to the rising incidence
of severe infections and fuel the growth of the hospital market. In contrast,
the community market is facing a value loss resulting from the patent expiries
of blockbusters such as Zithromax (azithromycin) and the incursion of cheap
generics.
Reasons to Purchase
- Review the clinical and commercial factors driving new product decisions
in antibacterials, and the opportunities and threats facing the market
- Gain insight into future trends and lifecycle management strategies
through a detailed market forecast and real case study analyses
- Understand where concerns, unmet needs and future opportunities lie by
learning about the views of key antibacterial opinion leaders.
| 
View Cart
